Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion type Assertion NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_head.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion description "[The Mdm2 inhibitor nutlin-3 was evaluated alone and in combination with cisplatin in a panel of germ cell tumour (GCT)-derived cell lines (embryonal carcinomas, being the nonseminomatous stem-cell component) with wild-type (NT2 and 2102EP cells) and mutant (NCCIT cells) p53 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_provenance.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion evidence source_evidence_literature NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_provenance.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion SIO_000772 19560254 NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_provenance.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion wasDerivedFrom befree-20140225 NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_provenance.
- NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_assertion wasGeneratedBy ECO_0000203 NP685364.RAZxdU9qFaLvVARUQUT_7ZIee8naRHOEkLmDTfzUUr-Og130_provenance.